This was inspired by the positive effects of SGLT2 inhibitors in patients with metabolic and inflammatory pathologies, such as DM2 [80] and associated heart failure [81], diabetic cardiomyopathy and nephropathy [80], decrease in cognitive functions, non-alcoholic fatty liver disease (NAFLD) [82], hypertension [83], and other pathologies [11]. The gene discussed is SLC5A2; the disease is kidney disorder.